SBI Healthcare Opportunities Fund has outperformed its category, recording a 21.4% return over the past year. While its performance highlights the strength of its pharmaceutical and healthcare holdings, investors should remain aware of the high volatility and concentration risk associated with sectoral funds.
The SBI Healthcare Opportunities Fund has emerged as a top performer among pharmaceutical and healthcare mutual funds, delivering a 21.4% compound annual growth rate (CAGR) over the past year. This performance places the fund ahead of notable peers, including Mirae Asset Healthcare Fund, which reported a 19.9% return, and DSP Healthcare Fund, with a 15.2% return over the same period. The fund, which currently manages assets of approximately ₹4,997.72 crore, has also significantly outperformed its benchmark, showcasing the effectiveness of its current stock-picking strategy.
Sectoral Concentration and Portfolio Composition
Unlike diversified equity funds that spread investments across many industries, this fund is a sectoral or thematic product. It focuses exclusively on the healthcare and pharmaceutical sector. Its recent gains are largely linked to the performance of its major holdings, which include prominent companies such as Sun Pharmaceutical, Divi's Laboratories, and Apollo Hospitals. Because the fund is heavily concentrated in one industry, its net asset value (NAV) is highly sensitive to sector-specific changes. This means that when the pharmaceutical sector thrives, the fund tends to perform well, but it can also be more susceptible to sharp drops if the sector faces regulatory pressure, price caps, or weak demand.
Understanding Investor Risks
Investors considering such funds should note that sectoral concentration brings inherent risks. A downturn in the healthcare industry can lead to larger losses compared to a broader market index. Furthermore, the fund is classified as a 'Very High' risk investment. There are also practical costs to consider, such as an exit load of 0.50% if units are redeemed within 15 days of purchase. From a tax perspective, short-term capital gains are taxed at 20%, while long-term capital gains exceeding ₹1.25 lakh are taxed at 12.5%.
What Investors Should Monitor
For those invested or looking at this category, future performance will depend on the broader health of the pharmaceutical sector. Key monitorables include government pricing policies for medicines, global export demand for Indian drugs, and any regulatory actions affecting major companies in the portfolio. While the fund has delivered strong short-term results, tracking its performance over longer periods and maintaining a balanced view of sectoral risks is essential for managing a portfolio effectively.